Cvrx, Inc. ( (CVRX) ) has released its Q3 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CVRx, Inc. is a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, with its flagship product, Barostim, being the first FDA-approved technology of its kind for heart failure patients.
In its third-quarter 2025 financial results, CVRx reported a 10% increase in total revenue compared to the previous year, reaching $14.7 million. The company also highlighted the growth of active implanting centers in the U.S. and the favorable CMS ruling on physician fee payment levels, which are expected to enhance patient access and adoption of their Barostim technology.
Key financial metrics showed U.S. revenue at $13.5 million, driven by expansion into new sales territories and increased awareness of Barostim. European revenue also saw a 12% increase, although total revenue units decreased. The gross profit rose by 15%, with a notable improvement in gross margin due to higher selling prices and manufacturing efficiencies. However, the company reported a net loss of $12.9 million, slightly improved from the previous year’s $13.1 million loss.
Looking ahead, CVRx has updated its full-year revenue guidance to between $55.6 million and $56.6 million, with expectations of continued gross margin improvements. The company remains focused on expanding its market presence and enhancing the adoption of its Barostim technology, positioning itself for future growth in the cardiovascular medical device sector.